[PDF][PDF] Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in …
Journal of clinical oncology, 2015•researchgate.net
Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia
mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-
ribose) polymerase inhibitor olaparib. We compared the efficacy of olaparib plus paclitaxel
(olaparib/paclitaxel) with paclitaxel alone in patients with recurrent or metastatic gastric
cancer and assessed whether low ATM expression is predictive of improved clinical
outcome for olaparib/paclitaxel.
mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-
ribose) polymerase inhibitor olaparib. We compared the efficacy of olaparib plus paclitaxel
(olaparib/paclitaxel) with paclitaxel alone in patients with recurrent or metastatic gastric
cancer and assessed whether low ATM expression is predictive of improved clinical
outcome for olaparib/paclitaxel.
Purpose
Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared the efficacy of olaparib plus paclitaxel (olaparib/paclitaxel) with paclitaxel alone in patients with recurrent or metastatic gastric cancer and assessed whether low ATM expression is predictive of improved clinical outcome for olaparib/paclitaxel.
researchgate.net
